Skip to main content
. 2022 Apr 9;157(3):475–485. doi: 10.1007/s11060-022-03991-z

Table 2.

Neuro-oncology multidisciplinary team meetings at HP participants' worksite

N = 42 (100%)
Neuro-oncology meeting at worksite
 Yes 40 (95)
 No 2 (5)
Percentage of patients newly-diagnosed with HGG discussed at MDT meetingsa
 0—50% 7 (19)
 55—95% 7 (19)
 100% 23 (62)
Frequency of formal MDT meetingsa
 Weekly 16 (40)
 Fortnightly 16 (40)
 Monthly 7 (18)
 Other 1 (3)
Disciplines which attend most MDT meetings (either in person or remotely)a,b
 Neurosurgeon 39 (100)
 Medical oncologist/neuro-oncologist 39 (100)
 Pathologist/neuropathologist 37 (95)
 Radiation oncologist 37 (95)
 Radiologist 34 (87)
 Care coordinator 30 (77)
 Neurosurgery nurse 15 (38)
 Clinical trials coordinator/staff/researchers 12 (31)
 Neurologist 8 (21)
 Radiation oncology nurse 5 (13)
 Social worker 5 (13)
 Psychiatrist 5 (13)
 Medical oncology nurse 4 (10)
 Occupational therapist 4 (10)
 Palliative care specialist 4 (10)
 Palliative care nurse 3 (8)
 Nuclear medicine physician 3 (8)
 Physiotherapist 2 (5)
 Neuropsychologist 2 (5)
 Speech therapist 1 (3)
 Otherc 4 (10)

a one HP did not answer this question

b multiple responses allowed

c Other included: radiation therapists (n = 2); MDT coordinator (n = 1); and trainee (n = 1)